Core Insights - Stryker reported quarterly earnings of $3.19 per share, exceeding the Zacks Consensus Estimate of $3.14 per share, and showing an increase from $2.87 per share a year ago, representing an earnings surprise of +1.59% [1] - The company achieved revenues of $6.06 billion for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 0.24% and increasing from $5.49 billion year-over-year [2] - Stryker has consistently surpassed consensus EPS and revenue estimates over the last four quarters [2] Earnings Performance - The earnings surprise for the previous quarter was +2.29%, with actual earnings of $3.13 per share compared to an expected $3.06 per share [1] - The current consensus EPS estimate for the upcoming quarter is $4.39, with projected revenues of $7.07 billion, and for the current fiscal year, the EPS estimate is $13.50 on revenues of $25 billion [7] Market Position - Stryker shares have increased by approximately 2.7% since the beginning of the year, while the S&P 500 has gained 17.2%, indicating underperformance relative to the broader market [3] - The Zacks Rank for Stryker is currently 3 (Hold), suggesting that the stock is expected to perform in line with the market in the near future [6] Industry Outlook - The Medical - Products industry, to which Stryker belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, which may impact stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]
Stryker (SYK) Q3 Earnings and Revenues Beat Estimates